Navigation Links
Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy

ose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

Contact

Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.com
or
Strategic Growth International, Inc.
Richard Cooper, 212-838-1444
rcooper@sgi-ir.com
Miri Segal, 212-838-1444
msegal@sgi-ir.com
Jennifer Zimmons, 212-838-1444
jzimmons@sgi-ir.com
or
Segue Ventures LLC
Craig Bird, 215-885â??4981
CHBird@segue.biz
or
Investorsâ?? Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/


'"/>




Page: 1 2 3

Related medicine technology :

1. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:8/3/2015)... , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... therapy to treat obesity, metabolic diseases and other gastrointestinal ... has been appointed to the Board of Directors, effective ... Class II Director until the 2018 annual meeting or ... Ms. McDougal has served in an executive capacity in ...
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, ... announced a strategic collaboration to discover and develop ... The new collaboration builds on a broad existing ... strategic approach in these therapeutic areas using novel ... extend use of its antisense technology to diseases ...
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
Breaking Medicine Technology:EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that its ... per share, payable on December 15, 2009 to shareholders ... quarterly dividend of $0.0625 per share represents a twelve ... last four quarters. , Perrigo Company is a ...
... /PRNewswire-FirstCall/ -- Shire plc ... biopharmaceutical company, announced today that it will present key scientific ... (TM) (guanfacine) Extended Release Tablets, Vyvanse ... ®( ) (methylphenidate transdermal system) CII, at a national ...
Cached Medicine Technology:Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 2Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 3Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 4Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 6Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 7Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 8Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 9
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... , Infectious diseases researchers from the University of Pittsburgh School of Medicine are ... of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine ... reduce health care costs. , Annually, more than 8.6 million adverse drug ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... Hispanic Health notes that while an overwhelming number of Hispanics believe people ... , The overwhelming 70 percent of participants queried said making diet changes was ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... solutions for drugs, biologics and consumer health products, today welcomed the announcement by ... OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... must weigh risks, benefits, experts say , , TUESDAY, Nov. ... data confirms that some common inhalers don,t boost the ... as chronic obstructive pulmonary disease (COPD). , In fact, ... in patients with COPD, the fourth biggest killer in ...
... 25 Nationwide Health Properties, Inc. (NYSE: NHP ) ... U.K. nursing home property company that may be in default ... the similarity of the names, it wanted to clarify that ... , Nationwide Health Properties, Inc. is a real ...
... (FRG) is pleased to announce the hiring of Dr. ... Operations. Katyal will be joining them from,West Penn Hospital, ... and Past President of the Pittsburgh Radiology Society. , ... widely regarded as the preeminent cardiovascular imager in,Western Pennsylvania. ...
... public event held today in New Orleans, the Department ... jointly announced the selection of adjacent downtown sites for ... projects, called the Veterans Affairs Medical Center and the ... greatly needed health care capability lost in New Orleans ...
... Nov. 25 The U.S. military provides its members ... commitments. But a researcher at Kansas State University ... be enough to maintain a supreme equilibrium. , ... of psychology at K-State, and colleagues have been studying ...
... components to determine levels of halogens , ... Minneapolis ... a leading materials testing laboratory, is helping companies adhere ... led to concerns regarding the environmental and health impact of halogens ...
Cached Medicine News:Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 3Health News:Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff 2Health News:VA and Louisiana State University Announce Site Selections for New Orleans Medical Center Projects 2Health News:VA and Louisiana State University Announce Site Selections for New Orleans Medical Center Projects 3Health News:K-State Psychologist Studies Ways to Improve Soldiers' Work-Life Relationship 2Health News:Innovatech Labs, Assisting Companies in Adhering to Halogen-Free Manufacturing Standards Aimed at Protecting the Environment 2
Galilean Loupes...
... Over 40 cm field-of-view enables high-quality ... system with scalable 32-channel architecture. New powerful ... 3.0T imaging up to 80 mT/m ... SAR management to fully exploit the power ...
... fusion system represents a breakthrough for patients ... spine. The system gathers bone during decompression, ... of bone into the implant's chamber produces ... harvest from the iliac crest. The BAK/C ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: